Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.
about
Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System InfectionsTuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsNeurotuberculosis immune reconstitution inflammatory syndrome in the setting of HIV infection: A case report and review of literature.Inflammasome Activation Underlying Central Nervous System Deterioration in HIV-Associated Tuberculosis.Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand.TB-IRIS: Proteomic analysis of in vitro PBMC responses to Mycobacterium tuberculosis and response modulation by dexamethasoneThe impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort studyEffectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort studyRandomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndromeManagement of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Timing of antiretroviral therapy for HIV in the setting of TB treatment.Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome.Epidemiology of HIV-associated tuberculosis.Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settingsIncidence and predictors of tuberculosis among adult people living with human immunodeficiency virus at the University of Gondar Referral Hospital, Northwest Ethiopia.Timing of initiation of antiretroviral drugs during tuberculosis therapy.Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients.Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcomeHypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndromePathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.Six-month survival of critically ill patients with HIV-related disease and tuberculosis: a retrospective study.HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling.Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors.Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospectivThe immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome.HIV-1 tuberculosis-associated immune reconstitution inflammatory syndromeHIV-1 and the immune response to TB.New drugs and regimens for treatment of TB.Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome.Immune restoration diseases reflect diverse immunopathological mechanisms.Management of individuals requiring antiretroviral therapy and TB treatment.Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trialIs vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?Immune reconstitution inflammatory syndrome in a HIV-infected patient with disseminated tuberculosis.
P2860
Q26774211-FC0C4FC2-0B91-44B4-AD0A-20C3519AD174Q28749315-470B117F-7820-4146-B918-16567361762CQ31155487-057E204E-1ED2-4020-8D8A-D44B1E7AA04FQ33553788-0468A7DE-BBD7-4B0C-80F4-1EBA4B138D5BQ33686938-9DB124BB-F480-4B43-AC05-B151BAB72BD8Q33732480-A305412E-57C1-4261-A157-CC69F9218FFAQ33758612-2618BF27-3B42-4899-BCAB-E1DEBCE66B8DQ33894801-CCC7ABC3-A4A7-489A-BD89-7BEE674C4FD2Q34130659-9168BD17-1488-455A-8CB2-8BD078790C65Q34455442-8B17BA67-36CF-422A-9E8A-37DA1DD5647DQ34475542-0CE79731-0C9C-4039-AAB7-17BCCC9DB59FQ34477198-05AA53E3-B529-4B15-B7C4-08327F3CECE8Q34488659-85C65F8B-9CC6-45B9-BA22-7A06BCCDDCFAQ34519940-1182116C-6392-42AC-ABDA-BB4D4E8A4974Q34746206-76B0F747-920A-47BB-A169-6C3922FE823BQ34785986-F88FB580-1759-413C-8C65-F62F122EF687Q34790184-7209DD41-6BAD-4785-A115-7F3D217EFED9Q34979146-A81AE616-B90C-45B9-BE42-5ECD73265228Q35043048-E2F31177-DBD0-4503-92A1-9FAD9DBEB48AQ35060755-6CA35849-1C28-4340-B3DC-B89981695278Q35075811-0031603B-F9B5-4441-9578-6D005D109F08Q35622163-43D8F842-DE5A-4EBF-AF90-8C09B2676004Q35656939-79D24112-A6C9-4817-9213-2E0E8A7569A1Q35711609-AAA5ED40-847A-4372-AAE9-76576A812EE2Q35890799-194B153F-2F99-48DA-869B-CC83366359B7Q36048584-0F12AEEA-A023-4A2B-AA1B-2DFC145875AAQ36129630-E4A39C72-AEFF-4F61-A479-A603F358F46BQ36146226-C6672E57-4DCD-4B4A-B141-9C7BF23933FAQ36219464-A8AE90B5-5F57-4F54-A706-6E4644283E55Q36501447-BF87812D-631D-4DED-A728-30208EBD50CCQ36517790-01C1631B-4DA7-4515-A480-2BF5088BB7C5Q36654015-C1D20DB8-210B-48CF-91BC-7CF59E858FDBQ36815449-C117334E-C210-4F18-A9AA-965B596045DEQ36825354-67BFB44D-683A-4F43-9626-7BEF6BD1DF6BQ36994158-7D7D4049-8D38-4957-A3DB-A6D2F98CAB33Q37409995-444D6E16-0EDB-4FFF-B11F-1ABC1B9C144FQ37666456-5C2CA836-3007-4029-B373-C7DC76456CB1Q37699575-2609B5A9-EBD7-475A-8693-7FC53F0C2BE6Q38951653-BCC1A8F0-5338-4A04-9895-EC714112AA94Q40230527-13BB5871-DBF6-4ADE-A27B-1FE3B751166D
P2860
Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Frequency, severity and durati ...... s in HIV-related tuberculosis.
@en
type
label
Frequency, severity and durati ...... s in HIV-related tuberculosis.
@en
prefLabel
Frequency, severity and durati ...... s in HIV-related tuberculosis.
@en
P2093
P1476
Frequency, severity and durati ...... ts in HIV-related tuberculosis
@en
P2093
P304
P577
2007-12-01T00:00:00Z